SM08502

DRUG2 trials

Sponsors

Biosplice Therapeutics, Inc.

Conditions

Castration-resistant Prostate CancerColorectal CancerNon-small Cell Lung CancerSolid Tumor, Adult

Phase 1

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

TerminatedNCT03355066

Biosplice Therapeutics, Inc.Solid Tumor, Adult

Start: 2017-11-06End: 2022-11-14Updated: 2024-08-09

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

TerminatedNCT05084859

Biosplice Therapeutics, Inc.Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer

Start: 2021-11-03End: 2022-10-20Updated: 2024-08-09

Related Papers

Abstract 1167: The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of pediatric medulloblastoma patient-derived orthotopic xenograft mouse models.

Cancer Research2026-04-03

Abstract CT112: Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors

Cancer Research2021-07-018 citations

Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models

Cancer Research2020-08-155 citations

Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models

Cancer Research2020-08-151 citations

Abstract 3521: Transcriptome analysis of TCGA prostate cancer samples identifies an association of poorer survival and aggressive disease biology with CDC-like kinase (CLK) expression and spliceosome regulation

Cancer Research2020-08-15

Abstract A09: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models

Clinical Cancer Research2020-07-01

Abstract P3-13-01: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects as monotherapy and in combination with chemotherapy in triple-negative breast cancer (TNBC) models

Cancer Research2020-02-15

Abstract A02: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models

Cancer Research2019-12-131 citations

Abstract C09: Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models

Cancer Research2019-12-131 citations

Abstract C08: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates activity against cancer stem cell (CSC)-enriched pancreatic cancer cells and suppresses stemness in vitro

Cancer Research2019-12-13

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

Cancer Letters2019-09-24139 citations

Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt pathway signaling, on gene expression and antitumor activity in colorectal cancer (CRC) models.

Journal of Clinical Oncology2019-05-203 citations